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Summary 
Immune surveillance against umors usually depends on T cell recognition of  tumor antigens 
presented by major histocompatibility complex (MHC) molecules, whereas MHC class I tu- 
mors may be controlled by natural killer (NK) cells. Perforin-dependent cytotoxicity is a major 
effector function o fCD8 + MHC class I-restricted T cells and of NK cells. Here, we used per- 
forin-deficient C57BL/6 (PKO) mice to study involvement of perforin and Fas ligand in tu- 
mor surveillance in vivo. 
We induced tumors in PKO and normal C57BL/6 mice by (a) injection of  different synge- 
neic tumor cell lines of  different issue origin in naive and primed mice; (b) administration of  
the chemical carcinogens methylcholanthrene (MCA) or 12-O-tetradecanoylphorbol-13-ace- 
tare (TPA) plus 7,12-dimethylbenzanthracene (DMBA), or (c) by injection of  acutely onco- 
genic Moloney sarcoma virus. The first set of  models analyzes the defense against a tumor load 
given at once, whereas the last two sets give information on immune defense against umors at 
the very moment of  their generation. Most of  the tumor cell lines tested were eliminated 10- 
100-fold better by C57BL/6 mice in an unprimed situation; after priming, the differences were 
more pronounced. Lymphoma cells transfected with Fas were controlled 10-fold better by 
PKO and C57BL/6 mice when compared to untransfected control cells, indicating some role 
for FasL in tumor control. MCA-induced tumors arose more rapidly and with a higher inci- 
dence in PKO mice compared to C57BL/6 or CDS-deficient mice. DMBA+TPA- induced 
skin papillomas arose with similar high incidence and comparable kinetics in both mouse 
strains. C57BL/6 and PKO mice have a similar incidence ofMoloney murine sarcoma nd leu- 
kemia virus-induced sarcomas, but tumors are larger and regression is retarded in PKO mice. 
Thus, perform-dependent cytotoxicity is not only a crucial mechanism of  both cytotoxic 
T lymphocyte- and NK-dependent resistance to injected tumor cell lines, but also operates 
during viral and chemical carcinogenesis n vivo. Experiments addressing the role of Fas- 
dependent cytotoxlcity by studying resistance to tumor cell lines that were stably transfected 
with Fas neither provided evidence for a major role of  Fas nor excluded a minor contribution 
of  Fas in tumor surveillance. 
T umor cells arise in individuals as a result of  exposure to rnutagenic hemicals, radiation, viruses, or spontane- 
ous mutations (1). Whether or not an individual succumbs 
to the tumor depends on the balance between growth ki- 
netics and metastatic apacity of  the tumor versus the abil- 
ity of  the host to control the tumor. For this, the host has 
two major mechanisms at its disposal: innate and acqmred 
immunity. Innate immunity (e.g., NK cells) is not antigen 
specific and is able to act quickly and without priming. Ac- 
quired immunity depends on primxng, is therefore rela- 
tlvely slow but highly specific, and has a memory. A tumor 
can prime acquired immunity if it presents tumor-specific 
antigens in the context of  MHC class I or class II molecules 
to CD8 + or CD4 + T cells, respectively (1-3). Further- 
more, expression of  costimulatory molecules (e.g., B7, in- 
tracellular adhesion molecule-I, and LFA-3) has been shown 
to dramatically increase the efficiency of  prinung in certain 
instances (4-7). Under selective pressure, however, tumor 
escape variants that lack MHC class I or II molecules, co- 
stimulatory molecules, or tumor-specific antigens (8-11) 
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may arise. Some escape variants that had lost MHC class I 
expression are efficiently controlled in vivo by NK cells 
(12, 13) in a strictly perforin-dependent way (13). 
Perforin-deficient (PKO) 1 mice have been generated on 
a C57BL/6 genetic background (H-2 b) by homologous 
recombination and are healthy under specific pathogen- 
free conditions (14). PKO mice completely lack perforin- 
dependent cytotoxicity, whereas the Fas (CD95)/FasLigand 
(FasL)--dependent cytotoxic pathway is unimpaired (14-22). 
Therefore, PKO mice allow the assessment of the relative 
contribution of each of the two major cell-mediated cyto- 
toxic pathways to a variety of immune responses in vivo 
and in vitro (14, 15, 17-22). We have shown previously 
that the defense against infection with the noncytopathic 
lymphocytic horiomeningitis virus (LCMV) or, to a lesser 
extent, with the intracellular bacterium Listeria monocyto- 
genes depends on perforin-dependent cytotoxicity (14, 17, 23). 
Control of syngeneic MC57G fibrosarcoma cells was 10-fold 
better in C57BL/6 mice compared to PKO mice (14). 
Also, the development of insuhn-dependent diabetes melli- 
tus in a transgenic model (24) is perforln dependent. On 
the other hand, PKO mice were normal with respect o 
control of infection with cytopathic viruses like vaccinia vi- 
rus (VV) or Semliki forest virus (25). Finally, a role for per- 
forin-dependent cytotoxicity was demonstrated in rejection 
of MHC class 1-disparate allografts uch as heart (26) and 
allogeneic tumor cell lines (27), as well as in mixed lym- 
phocyte reactions in vitro (14, 15), and in GVHD (28). 
Here, we evaluate the role of perforin- and Fas-depen- 
dent cytotoxicity in the control of a variety of established, 
transplantable syngeneic MHC class I + tumor cells in vivo 
and assess the susceptibility of PKO mice to primary indi- 
vidually arising tumors induced by chemical carcinogens 
and by an oncogenlc virus. 
thracene-induced T lymphoma (American Type Culture Collec- 
tion [ATCC], Rockville, MD). B16 is a spontaneous melanoma, 
MC57G is a methylcholanthrene-induced fibrosarcoma (31), and 
MBL-2 is Moloney virus-reduced lymphoma. N1 are EL-4 cells 
stably transfected with the nucleoprotein (NP) of vesicular stoma- 
titis virus (VSV), and V1 is a mock-transfected control (N1 and 
V1 were originally obtained from L. Lefrancois, Division of 
Rheumatology, Connecticut Health Center, Farmington, CT; 
32). SR23B adenovirus type 5 early region I (Ad5EI) + EJras 
transformed tumor cell line was generated from mouse embry- 
onic cells as described previously (33) and contains an Ad5E1B- 
encoded CTL epltope. All cell lines were of C57BL/6 origin and 
were maintained in IMDM supplemented with 5% FCS and anti- 
biotics. 
Monoclonal rat anti-mouse CD4 (YTS191.1) and monoclonal 
rat anti-mouse CD8 (YTS169.4) were originally obtained from 
Dr. H. Waldmann (Dunn School of Pathology, Oxford, UK; 34). 
Treatment involved injection of 2 mg l.p. of the appropriate anti- 
body. Efficiency of depletion was checked by FACS ® analysis 
(Becton Dickinson & Co.). Purified monoclonal hamster anti- 
mouse TNF-0~ TN3-19.12 has been described (35) and was 
kindly provided by Dr. R. Schrelber (Washington School of 
Medicine, St. Louis, MO); TN3-19.12 was used in vivo at 0.25 
mg/wk (two injections maximal) to neutralize TNF-ot. 
VSV Indiana (Mudd-Summer isolate) was originally obtained 
from Dr. D. Kolakofsky (University of Geneva, Geneva, Switzer- 
land) and were grown on BHK21 (baby hamster kidney, ATCC 
CRL 8544) cells infected with low multiplicity of infection (moi) 
and plaqued on Veto cells. VV expressing the NP of VSV (VV- 
VSV-NP) was kindly given by Dr. B. Moss (National Institutes of 
Health, Bethesda, MD; 36). VV expressing FasL has been de- 
scribed (37). All VV stocks were made on BSC40 cells. LCMV, 
isolate WE (LCMV-WE), was initially obtained from Dr. F. Leh- 
mann-Grube (Heinnch-Pette Institfit fiir Experimental Virologie 
und Immunologle, Universlt~it Hamburg, Germany; 38) and was 
propagated in L929 fibroblast cells. Moloney murlne sarcoma nd 
leukemia virus (MoMSV) complex was prepared and tltered as 
described previously (39). 
Materials and Methods 
Mice 
Inbred C57BL/6 mice were obtained from the Institute ffir 
Zuchthygiene (University of Zi.irich, Switzerland). PKO (14), CD8- 
deficient mice (CD8-/-; 29), and RAG-2-deficient mice 
(1LAG2-/-; 30) have been described before and were bred under 
specific pathogen-free conditions in our own facilities. PKO mice 
had a C57BL/6 (H-2 b) background. Mice at least 7 wk old were 
used in all experiments hat were performed according to can- 
tonal and federal laws on animal protection, which requires use of 
minimal numbers of experimental animals. 
Cell Lines, Antibodies, attd Viruses 
RMA is a mutagenized RBL-5 (Kauscher virus-reduced T lym- 
phoma [12]) cell line. EL-4 is a 9,10-dimethyl-l,2-benzan- 
IAbbrewatlons u ed in this paper: DMBA, 7,12-dimethylbenzanthracene; 
FasL, Fas hgand; LCMV, lymphocyUc chorlomeningitis virus; LCMV- 
WE, LCMV isolate WE; MCA, methylcholanthrene; moi,multlphclty of
infecuon; MoMSV, Moloney munne sarcoma virus, NP, nucleoprotem; 
PKO, perforin-deficlent (mice); TPA, 12-O-tetradecanoylphorbol-13-ace- 
tare; VSV, vesicular stomatms virus; VV, vaccmta v~rus. 
Transfection of Cell Lines with Fas 
MBL-2 cells were stably transfected with a construct carrying 
the mouse Fas gene and the neomycin resistance gene (kindly 
provided by Dr. P. Golstein, Centre d'Immunologle INSERM- 
CNRS, Marseille, France; 22) by electroporation a d were subse- 
quently selected with 0.9 mg/ml geneticm (G418; Glbco BRL, 
Basel, Switzerland). G418-resistant cells were checked for Fas ex- 
pression by FACS ® analysis: 1 million cells were incubated with 
10% normal hamster serum (15 rain at 4°C) followed by biotin- 
labeled hamster anti-mouse Fas (Jo-2: PharMlngen, San Diego, 
CA) mAb. Cells were stained with streptavldin-FITC or strepta- 
vldin-PE. Fas + cell lines were subcloned by limiting diluuon. 
MBL-2 and MBL-2.Fas cells were insensitive to TNF-mediated 
cytotoxiclty in vitro (data not shown). 
Fas-dependent Cytotoxicity Assay 
To test whether the transfected Fas was funcuonal, Fas-trans- 
fected (Fas ÷) and control (Fas) cell lines were labeled with 
Na51CrO4 and were used as targets for FasL + effectors. FasL + ef- 
fectors were generated by infecting MC57G fibroblasts with VV- 
FasL (37) for 2 h with a multiplicity ofinfectin (moi) of 2. Effec- 
tors and targets (104 per well) were incubated for 5 h at 37°C in 
a standard 51Cr release assay. In addition, PKO and control 
1782 Tumor Surveillance in Perforin-deficlent Mice 
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Table 1. C57BL/6-derived Tumor Cell Lines 
Tumor Class I* Class II* Fas* Fas-mediated lysis* 
MC57G MCA fibrosarcoma 330 3 8 0 
MBL-2 Moloney B lymphoma 1,100 3 21) 0 
MBL-ZFas Moloney B lymphoma, 1,200 3 250 54 
Fas transfected 
EL-4 DMBA T lymphoma 1,500 3 28 4 
1KMA Rauscher T lymphoma 1,300 3 33 6 
B 16 Melanoma 40 3 10 0 
S1K23B Adeno-transfected 75 3 10 0 
embryonic ells 
*Cells were stained with biotin-labeled anti-MHC class I, anti-class II or ann-Fas mAb, followed by streptavidm-PE. Surface expression of all cell 
lines was measured by FACS ® (CellQuest software) xn one expenment and given m arbitrary umts with the fluroescence of second stage antibody 
alone set at 3. 
:~Percentage specific killing by VVFasL-infected MC57G effector cells at an E/T ratio of 10 m a 5-tl S~Cr elease assay. 
C57BL/6 mice were infected intravenously with 200 PFU 
LCMV-WE. 8 d later, their spleens were tested in a CTL assay 
for LCMV-specific cytotoxicity on SlCr-labeled, LCMV peptide 
(GP33, lmmunodomlnant CTL epitope in H-26 mlce)-loaded 
targets (40). Percentage of specific SlCr release = [(experimental 
release - spontaneous release)/(maxlmal release - spontaneous 
release)] × 100%. 
Tumor Induction In Vivo by Injection of Tumor Cell Lines 
Normal Untreated Mice. PKO and C57BL/6 mice were in- 
jected intraperitoneally with different amounts of viable tumor cells 
(Table 1). Mice were monitored daily for tumor growth by de- 
termining their weight; they were killed if the weight increased 
to more than 15% compared to noninjected controls. In case of 
S1K23B cells, subcutaneous tumor volume was deterrmned with a 
caliper measuring two perpendicular diameters. 
Effect of Priming with Viral Antigens. PKO and C57BL/6 mice 
were primed intravenously with 2 × 10 ~' PFU VSV, with 2 X 
106 PFU VV-VSV-NP, or were left unprimed. After 14 d, mice 
were rejected lntraperitoneally with different numbers of N1 
(EL-4 thymoma expressing VSV-NP) or V1 (control EL-4), and 
tumor growth was momtored. 
Effect of Priming with Tumor Antigens. PKO and C57BL/6 mice 
were primed intrapentoneally with 5 X 10 ~ irra&ated (100 Gy) 
MBL-2 cells in 0.2 nil PBS on days 0 and 7. On day 14, mice 
were rejected intraperitoneally with different numbers of viable 
MBL-2 or MBL-2.Fas cells and were monitored tbr tumor 
growth. Alternatively, mice were primed subcutaneously with 
107 irradiated (25 Gy) SR23B cells m 0.1 ml PBS on days 0 and 
14 and challenged subcutaneously on day 28 with the same num- 
ber of SR23B cells. 
Male mice were used for all experiments to avoid possible tu- 
mor rejection caused by T cells recognizing the male antigen H-Y. 
Tumor Induction by Tumorigenic Agents 
Carcinogenic Chemicals. Groups of 10 C57BL/6, PKO, and 
CD8 - /  mice were rejected subcutaneously in the left hind leg 
with 0.1 ml corn oil containing 25, 100, or 400 btg methyl- 
cholanthrene (MCA), and mice were monitored weekly for fi- 
brosarcoma development. 
1783 van den Broek et al. 
Alternatively, 100 ~1 acetone containing 10 nmol 12-O-tet- 
radecanoyl-phorbol-13-acetate (TPA) and 3 nmol 7,12-dlmeth- 
ylbenzanthracene (DMBA) was applied twice weekly on the 
shaved skin of the back to groups of eight C57BL/6 and PKO 
mice. Skin application was continued during the course of the 
experiment, and mice were observed twice per week for the de- 
velopment of papillomas (41). 
MoMSV. Groups of 5-10 C57BL/6 and PKO (untreated, 
anti-TNF-treated, CD4-  or CD8-depleted) or CD8 / -  mace 
were injected m the left thigh with 100 ILl PBS i.m. containing 
103 focus forming units of MoMSV complex, as has been de- 
scribed (39). Mice were monitored for tumor growth, and tumor 
size was determined using a caliper measuring two perpendicular 
diameters. 
Isolation and Culture of MCA-induced Sarcomas 
When MCA-mduced sarcomas had reached a volume of ~0.5 
cm 3, mice were killed and tumors were removed asepucally. Tu-  
mors were cut into small pieces and were trypsmlzed for 5 h at 
room temperature, clumps were removed, and single cells were 
cultured in IMDM supplemented with 10% FCS, glutamme, and 
antibiotics. Cells were split when they reached confluency. All 
sarcomas could be kept in culture for at least 3 too. The expres- 
sion of MHC class I, class II, and Fas was determined by FACS ® 
analysis. 
Statistical Analysis 
Results were compared statistically using the unpaired Mann-  
Whitney U test. 
Results 
Petforin Plays a Role in Surveillance against Most 
Established Tumor Cell Lines 
PKO mice and C57BL/6  mice were rejected w i th  syn- 
geneic tumor  cell l ines o f  different issue origins, and tumor  
growth  was moni tored .  
Tumors of Nonlymphoid Origin. B16 melanoma cells grew 
unrestr icted in both  C57BL/6  and PKO mice, even when 
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Table 2. Control of Syngeneic Tumor Cell Lines by C57BL/6 
and PKO Mice 
C57BL/6 PKO 
Tumor Primed* Unprimed Primed Unprimed 
MC57G ND 106 (4/4) ND 105 (4/4) 
MBL-2 >106 (6/6) 104 (6/6) 105 (6/6) <102 (6/6) 
MBL-2.Fas >106 (4/4) 105 (6/6) 106 (2/4) 103 (6/6) 
R.MA >106 (414) 104 (7•7) >106 (4•4) 104 (6•6) 
RdViA-S ND 104 (8/8) ND 102 (8/8) 
EL-4 >106 (6/6) 104 (6/6) <102 (6/6) <102 (6/6) 
B 16 ND 102 (3/3) ND 102 (3/3) 
The cell numbers in the table represent the lowest number of tumor 
cells that could not be controlled in vlvo. The numbers in brackets are 
the number of mice with tumors out of the total number tested which 
were obtained In two to three independent experiments with groups of 
two to three rmce. 
*Mice were primed with tumor cells (MBL-2, P, MA) by injection of 
5 X 106 irradiated tumor cells (MBL-2, MBL-2 Fas, P, MA) at days -14 
and -7  before tumor challenge at day 0 or with viral anugens (VSV, 
VV-VSV-NP) by ln lecnon of 2 × 106 PFU at day -14 betbre tumor 
(VSV-NP-transfected ormock-transfected EL-4) challenge at day 0. 
as little as 100 cells were injected. MC57G fibrosarcoma 
cells were control led 10-fold better by C57BL/6  mice than 
by PKO mice (Table 2) (14). In contrast, 107 adenovirus + 
ras-tranformed mouse embryonic  cells (SR23B) were re- 
jected by both unprimed mouse strains (Fig. 1). The tumors 
were smaller in PKO mice, suggesting even a better control 
by these mice. After pr iming with irradiated SR23B cells, 
both mouse strains were equally protected against tumor  
growth (data not shown). 
Tumors of Lymphoid Origin. EL-4 and MBL-2  cells were 
control led 100-1,000-fold better by naive C57BL/6  mice 
when compared to naive PKO mice (Table 2 and Fig. 4). 
Pr iming with tumor cells (MBL-2) even increased the re- 
sistance against subsequent challenge 100-fold in C57BL/6  
and PKO mice (Table 2). As previously shown (42), EL-4 
tumor  cells expressing a wral antigen derived from VSV 
(N1), but not their mock-transfected counterparts (V1) 
were readily control led by mice that had been previously 
pr imed with the virus (Fig. 2). In PKO mice, however,  
both N1 and V1 showed uncontrol led growth, indicating 
that this form of  ant i tumor immuni ty  ~s essentially medi -  
ated by perforin. P, MA cells, which are related to MBL-2  
cells, however,  were control led to a similar extent in both 
naive and pr imed C57BL/6  and PKO mice. The MHC 
class I -  derivative o f  RMA cells, P,.MA-S (12), was con-  
trolled considerably better by C57BL/6  mice (13). 
The data shown in Table 2 were obtained using two to 
three mice per group in two to three independent experi-  
ments in which established tumor cell lines were "titrated" 
into mice with 10-fold differences in cell number  injected. 
I f  a certain tumor  dose could not be controlled, then this 
5 x 105 SR23B s.c. 80 
70 --0-- B6 
60 ~ K O  
O 
N 40 
so  
~ 2o 
lO 
o 
5 10 15 20 25 
d 
Figure 1. Adenovlms + ras transformed mouse embryonic cells are 
controlled by perform-deficient mice. C57BL/6 (0) and PKO (©) mice 
were gaven 5 × 105 S1L23B cells (expressing AdSE1 and EJras) subcutane- 
ously on day 0, and tumor development was monitored Each line repre- 
sents an Individual mouse. 
was the case in 100% of  the mice tested and, in addition, a 
10-fold lower load o f  the same tumor  cell line was always 
controlled. An exception to this was formed by MBL-2.Fas 
cells in pr imed PKO mice: in both experiments, one out o f  
two mice control led 10 ° cells, and one out o f  two con-  
trolled 10 s cells, but died after 106 cells, albeit with a delay 
o f  2 wk  compared to the t ime mice usually died in these 
experiments (Fig. 4). 
Stable Transfection of MBL-2 Lymphoma Cells with 
Functional Fas 
MBL-2  cells were transfected with an expression vector 
encoding mouse Fas and G418 resistance by electropora- 
tion, and G418-resistant MBL-2  cells were subcloned 
twice. One  o f  the selected subclones (MBL-2.Fas9) dis- 
played a homogeneous  expression pattern o f  Fas (Fig. 3 A) 
and was killed by FasL + MC57G cells (Fig. 3 B). Spleno- 
>60 
50 
= 40 
Me- 
"~- -  20 
10 
• B6 ] ~  
o ,Ko I I 
e e o m o e  
z 
EL4 transfectant ~ "~ z ~ . 
injected >~ =o .~ o E 
priming none VSV VV-VSVnp 
Figure 2. Growth of syngenelc EL-4 thymoma cells in primed and 
unprlmed C57BL/6 and perform-deficient mice. Mice were primed at 
day 0 with 2 × 106 PFU live VSV, 2 × 10" PFU hve recombinant VV- 
expressing VSV-NP, or were left unpnmed. At day 14, mice were chal- 
lenged lntrapentoneally with 106 live VSV-NP-transfected or mock- 
transfected EL-4 cells Mice were observed ally for tumor growth by 
monitonng the weight of the mice. Mice were killed if the weight m- 
creased >15% compared to unlnjected mice. Each point represents one 
mouse. 
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80 
60 
40 
20 
0 
PKO 
effectors 
MBL-21GP33 
~MBL-2 .Fes lGP33 
81 27 9 3 
E/T ratio 
Figure 3. Lysls of Fas-transfected MBL-2 lymphoma cells by perform- 
deficient effectors. (A) Fas-expresslon of Fas- and mock-transfected 
MBL-2 cells. 106 cells were stained with a blotmylated monoclonal ham- 
ster anti-mouse Fas antibody 0o-1) followed by streptavidln-FITC. 
Viable cells were gated by a combination of forward and 90 ° side light 
scatter, and were analyzed with a FACScan ® cytofluorometer using loga- 
nthmic scales. Filled curve, MBL-2 cells; open curve, MBL-2 Fas cells. (B) 
Enhanced lysls of Fas + MBL-2 cells compared to Fas- MBL-2 cells by 
FasL-expressing effectors m vitro. MC57G cells were infected wxth VV- 
FasL (moi = 2) for 3 h and were used as effectors to kill SlCr-labeled 
MBL-2 and MBL-2.Fas target cells In a standard 5 h 51Cr release assay. 
The spontaneous release of MBL-2 and MBL-2.Fas target cells was 17 
and 14%, respectively. (C) Fas + MBL-2 cells are lysed by perforin-defi- 
cient effectors in vitro. PKO and control C57BL/6 mice were infected 
intravenously wath 200' PFU LCMV-WE. After 8 d, splenocytes (effec- 
tors) were analyzed for ex vivo cytotoxlc acUwty using LCMV-specxfic 
peptlde (GP33)-loaded MBL-2 or MBL-2.Fas target cells in a standard 
51Cr release assay. Lysls of MBL-2 and MBL-2.Fas without peptlde was 
<5% at the highest E/T ratio, and spontaneous release of targets was 
<18% 
cytes o f  PKO and C57BL/6  mice that had been infected 
with LCMV 8 d previously killed LCMV glycoprotein 
(GP)33-1oaded MBL-2.Fas cells to a similar extent (Fig. 3 C). 
As expected, untransfected MBL-2  cells (virtually Fas-, 
Fig. 3 A) were killed by C57BL/6  effectors, but only to a 
low extent b~¢ perfor in-def ic ient effectors (14); this sug- 
gested a major role for the perfor in-dependent  cytolytic 
pathway against Fas- or Fas l°w targets. Thus, transfection o f  
MBL-2  cells with Fas generated a cell line with a high, sta- 
ble, and functional expression o f  Fas. 
We also transfected MC57G and B16 cells with Fas and 
obtained clones with high expression. In vitro, however,  
these cells remained insensitive to Fas/FasL-mediated apop- 
tosis (data not shown), probably because o f  a lack o f  crucial 
intracellular signalling molecules downstream of  Fas (43). 
Therefore,  no in v ivo experiments were performed with 
MC57G.Fas  and B16.Fas cells. 
Resistance against Fas-transfected MBL-2  Cells 
To  evaluate whether  growth characteristics o f  MBL-2  
cells were inf luenced by Fas, MBL-2  and MBL-2.Fas cells 
were titrated intraperitoneally in RAG2 - / -  mice. In addi- 
tion, growth kinetics in vitro were compared. We did not  
observe differences in tumor  take or tumor  growth be-  
tween MBL-2  and MBL-2.Fas cells at the doses tested 
(102-104-106, RAG2 / -  mice could not control  the tu- 
mor) in RAG2 - /  mice or o f  proliferation in vitro (data 
not  shown). The potency o f  Fas/FasL interactions in tumor 
surveillance in v ivo was investigated in naive or pr imed 
mice. Naive C57BL/6  mice control led 103 MBL-2  cells 
and 104 MBL-2.Fas cells, but could not control an inoculum 
of  104 MBL-2  or 105 MBL-2.Fas. As little as 102 MBL-2  
cells grew in an uncontrol led fashion in PKO mice, whereas 
102 MBL-2.Fas cells were rejected (Fig. 4). This suggests 
that in an unpr imed situation, Fas/FasL interactions may 
contribute to tumor control. 
In a subsequent experiment,  mice were pr imed intra- 
peritoneally with 4 mil l ion irradiated MBL-2  cells. Mice 
were subsequently challenged with different numbers o f  vi -  
able MBL-2  or MBL-2.Fas tumor  cells, and tumor  growth 
was monitored.  Pr imed C57BL/6  mice control led the 
growth o f  >106 MBL-2  or MBL-2.Fas cells; on the other 
hand, pr imed PKO mice exhibited tumor  growth after in- 
ject ion o f  105 MBL-2  cells. Two out o f  four PKO mice 
could eliminate 105 MBL-2.Fas cells, whereas the other 
one displayed delayed tumor  growth (Table 2). Thus, 
pr iming with irradiated MBL-2  cells induced resistance 
>80 
|7 60 
=~ so 
, o  e~ 
~..e_ 3o 
"0  
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Figure 4. 
i i 
unpr imed 
O 
I I I 
10 2 10  3 104 10 s 106 
number  of cells injected 
B61MBL-2 
B61MBL-2.Fas 
PKOIMBL-2 
PKOIMBL-2.Fas 
t 
Growth of syngenelc MBL-2 and MBL-2.Fas lymphoma 
cells in naive C57BL/6 and PKO mace. PKO or control C57BL/6 mice 
were injected mtraperitoneally with different amounts of viable MBL-2 
or MBL-2.Fas lymphoma cells m 0.25 ml PBS. Mice were observed aily 
for tumor growth by momtonng the weight of the mace. Mice were 
killed if the weight increased >15% compared to uninjected control 
mice. Circles, MBL-2 cells, triangles, MBL-2.Fas cells; filled symbols, 
C57BL/6; open symbols, PKO. Each point represents one mouse. Cumu- 
lative data of three similar experiments (six rmce per group total) are 
shown. 
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Skin pap]lloma reduction by DMBA+TPA: independence 
of per~bnn. Groups of mght perform-deficient a d seven control C57BL/6 
rmce were treated tw]ce weekly wlth 3 nmol DMBA + 10 nmol TPA m 
acetone. The time of the appearance ofthe first papilloma was registered 
for each mouse. 
(Fig. 5, middle) or 400 Ixg (Fig. 5, bottom) induced sarcomas 
in C57BL/6  mice with an incidence of  80 and 100%, re- 
spectively. At all doses, a significant accelerated onset of  tu- 
mor (Fig. 5) and tumor size (data not shown) was observed 
in PKO mice. Administration of  100 Izg MCA to CD8 / -  
:3 e- 
5 
4 
3 
2 
1 
0 
0 
I 
50 100 
~100 Ilg 
O 
150 200 250 
days after MCA injection 
Figure 5. Control of MCA-lnduced carcinogenesis byperforin. PKO 
(O), CD8 ~ (A) and control C57BL/6 (O) nuce were lnoected subcuta- 
neously in the left flank with 25, 100, or 400 mxg MCA m 0 1 ml corn o11. 
Mice were observed every 5 d for palpable tumors. If tumors were >15 
mm in diameter, m]ce were killed. Experimental groups consisted of 5 
(25 txg, 400 b~g) or 10 (100 Izg) mine. Differences between PKO and 
C57BL/6 rmce were statistically significant (unpaired Mann-Whitney U 
test), whereas differences between CD8 - j -  and C57BL/6 mice were not 
against a >104- and a >103-fold higher dose of  MBL-2 in 
C57BL/6  and PKO mice, respectively. In C57BL/6  a 
>103-fold and in PKO an 103-fold higher protection was 
induced against MBL-2.Fas. 
Tumors hzduced by Chemical Carcinogens 
Subcutaneous injection of  MCA induced fibrosarcomas 
in a dose-dependent fashion. Injection of  25 bLg (Fig. 5, 
top) induced tumors in 100% of  the PKO,  but only in 20% 
of  the C57BL/6  mice. Administration of  100 Ixg MCA 
mice induced sarcomas with comparable kinetics and inci-  
dence as those seen in C57BL/6 mice. Experimental groups 
were statistically compared using the unpaired Mann-  
Whi tney  U test, and showed that tumor  development In 
PKO mice and C57BL/6  mice was statistically different af- 
ter injection of  100 Ixg MCA (P <0.0005) or 400 I.Lg 
MCA (P <0.009).  The difference between PKO and 
CD8 - / -  mice was also statistically significant (P <0.0008),  
whereas there was no difference between C57BL/6  and 
CD8 - /  mice (P = 0.9). Statistical analysis was not per- 
formed on groups injected with 25 I~g MCA,  because only 
one out of  five C57BL/6  mice, but five out of  five PKO 
mice, developed a sarcoma. FACS ® analysis performed 
within 10 d after isolation of  different MCA- lnduced  sar- 
comas showed that the sarcomas were MHC class I I°w/-, 
MHC class I I - ,  and Fas- (not shown). The expression of  
the above-ment ioned surface molecules was similar in the 
three different strains of  donor  mice. 
The first DMBA+TPA- induced  skin papillomas devel- 
oped in C57BL/6  and PKO mice after 18 wk and 21 wk, 
respectively, and 100% incidence was reached after 31.5 
and 34 wk, respecnvely (Fig. 6). The incidence and kinet-  
ics o f  DMBA+TPA- induced  papillomas were similar in 
PKO and C57BL/6  mice, arguing against a role for per- 
for in-mediated cytotoxicity (CTL and/or  NK) in the con-  
trol of  DMBA+TPA- induced  papillomas. 
Virally Induced Fibrosarcomas 
Intramuscular administration of  MoMSV to PKO and 
C57BL/6  mice led to tumor induct ion in all mice with 
similar kinetics. In addition, occurrence of  regression was 
not dependent on perforin (Fig. 7). Nevertheless, the tu- 
mors were larger on average and regression was retarded in 
PKO mice, suggesting involvement ofperfor in in the acute 
1786 Tumor Surveillance in Perfonn-deficlent Mice 
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Figure 7. Control of virally induced tumors by PKO mice PKO and 
control C57BL/6 nuce were given 103 focus forming units MoMSV in- 
tramuscularly in 100 Ixl PBS in the left hind leg. Mice were momtored 
regularly for palpable tumors. Each hne represents an individual mouse 
effector phase of  tumor rejection. CD8-depleted C57BL/6 
mice displayed similar tumor size and regression kinetics as 
PKO mice (not shown), indicating that CD8 ÷ T cells, and 
not NK  cells, exert the perforin-mediated effect. CD4-  
depleted C57BL/6 mice, on the other hand, developed 
large tumors that could not be eliminated (data not shown). 
We observed that PKO and C57BL/6 mice were sick and 
lost weight when the tumor reached its peak size. Treat- 
ment with anti-TNF-(x antibody abolished this sickness. 
Tumor size and kinetics of  regression, however, were not 
affected by this treatment. 
Discussion 
The perforin dependence of the eradication of  several es- 
tablished syngeneic tumor cell lines was investigated. Most 
cell lines showed a difference in tumorigenic dose between 
naive PKO and C57BL/6 mice, indicating that even with- 
out previous priming, perforin-mediated cytotoxicity is a 
crucial effector mechanism in tumor control. In primed 
mice, the difference between PKO and wild-type mice was 
even more clear. This suggests that priming of CD8 + CTLs 
1787 van den Broek et al. 
rather than priming o fCD4 + T cells is responsible for resis- 
tance to high tumor loads in C57BL/6 mice. 
Two tumor cell lines formed an exception to this rule. 
RMA cells showed equal growth in both naive (104) and 
pr imed (10 6) PKO and C57BL/6 mice, which may be ex- 
plained by the fact that control is mediated by perforin- 
independent mechanisms, probably by CD4 ÷ cells using an 
unidentified effector mechanism (1). Because RMA and 
MBL-2 are related lymphoma lines and express similarly 
high levels of  MHC class I and no MHC class II, and both 
cell lines are Fas l°w, the observation that the control of  
RMA is not dependent on perforin, whereas the control of  
MBL-2 cells is, was unexpected. This may be explained by 
a difference in efficiency of  priming CD4 + and/or CD8 + 
T cells, or by a different growth rate of  RMA vs. MBL-2 
cells. The second exception is formed by SR23B cells: this 
adenovirus + ras-transformed cell line induced larger tu- 
mors in C57BL/6 mice than in PKO mice. This unex- 
pected finding may be explained by the fact that PKO mice 
may have increased basal levels of  macrophage activation 
and/or cytokines uch as interferon-',/and TNF-oe as com- 
pensatory mechanisms, all of  which are known to possess 
antitumor activity. 
Stable transfection of  MBL-2 cells with Fas rendered 
them susceptible to Fas/FasL-dependent apoptosis in vitro. 
To investigate the contribution of  the Fas pathway to in 
vivo tumor surveillance, control of  MBL-2.Fas and MBL-2 
cells was compared in naive and primed PKO and C57BL/6 
mace. In unprimed PKO and C57BL/6 mice, Fas + cells were 
controlled 10-fold better compared to Fas- cells. Priming 
of PKO mice increased the number of  tumor cells needed 
for uncontrolled growth by 100-fold for both MBL-2 (10 4 
cells) and for MBL-2.Fas (10 s cells), suggesting priming of 
perforin-independent mechanisms. Priming of  C57BL/6 
mice, however, resulted in control of >106 MBL-2 or 
MBL-2.Fas cells, stressing the need for a collaboration be- 
tween perforin-dependent and -independent mechanisms 
for full immune protection against MBL-2 cells. Thus, our 
experiments failed to detect a major involvement of  Fas- 
dependent cytotoxicity in tumor control, but cannot ex- 
clude a minor role. 
To investigate the influence of  perforin on the induc- 
tion of  primary tumors in vivo, we analyzed ifferent mod- 
els in which tumors are induced by chemicals (MCA, 
DMBA+TPA)  or virus (MoMSV). The major difference 
of this approach compared to injection of  syngeneic ell 
lines is that the immune system is not confronted with a 
considerable tumor load at once, but that immunosurveil- 
lance is tested at the very moment a tumor arises. More- 
over, in contrast o injection of  homogeneous cell lines, 
each mouse develops its own tumor that may have individ- 
ually different umor antigens, even if the same chemical is 
injected in the same animal (44). Subcutaneous injection of  
MCA is known to induce sarcomas at the site of  injection 
(44) that usually do not regress once they developed. 
C57BL/6 and CD8 / mice developed sarcomas with a 
high incidence but with much slower kinetics than PKO 
mice. This suggests that NK cells or CD4 + T cells may act 
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directly or indirectly as important effectors controlling 
MCA- induced sarcomas. Ex vivo analysis of  MHC class I, 
class II, and Fas expression of  MCA- induced sarcomas, 
however, showed that sarcomas were Fas and MHC class 
I I -  and were MHC class I -/l°w, independent of  whether 
they were isolated from PKO, C57BL/6, or CD8 / mice. 
Although MHC class I expression could be upregulated to 
high levels by exposure to IFN-',/ in vitro (not shown), it 
remains unclear whether this occurs in vivo. Because four 
out of  four MCA- induced sarcomas tested were sensitive to 
NK-mediated lysis in vitro, this suggests that NK-mediated 
control may be an important pathway in vivo. In a second 
set of  experiments in which DMBA+TPA- induced skin 
papillomas were studied, no differences in incidence, kinet- 
ics, or size of  papillomas were observed between PKO and 
C57BL/6 mice, indicating that perforin does not play a key 
role. Because the latter model is immunologically not char- 
acterized (susceptibility of  SCID or nu/nu mice is not 
known), it ~s not possible at the present ime to be more 
specific about possible ffector mechanisms. 
Sarcomas induced by inoculation of  mice with MoMSV 
are known to be rejected within 3 wk by immunocompe-  
tent mice in which a prominent H-2Db-restricted CTL re- 
sponse is observed (45-48), whereas lethal tumors develop 
in nu/nu mice (Ossendorp, F., and C.J.M. Melief, unpub- 
lished data). Furthermore, CD4 depletion results in uncon- 
trolled tumor growth (Ossendorp, F., and C.J.M. Melief, 
unpublished ata). CD8 depletion, on the other hand, did 
not alter the incidence or kinetics of  tumor growth, but led 
to a significant delay in tumor rejection (data not shown). 
PKO mice &splayed a phenotype similar to CDS-depleted 
mice after inoculation w~th MoMSV, suggesting a distinct, 
perforin-dependent role for CD8 + CTLs in tumor control, 
although the tumor could be rejected without this path- 
way. It is not known at the present time which effector 
mechanism is used by CD4 + T cells to reject MoMSV-  
induced sarcomas, and this question is subject to further 
stu&es. Apparently, CD4 + T cells do not eradicate tumors 
through TNF-ot because treatment with neutralizing anti- 
TNF  antibodies in vivo improved the general well-being 
of  the mice at the peak of  the tumor growth, but did not 
interfere with tumor rejection (data not shown) indepen- 
dent of  mouse strain or treatment. 
Finally, during the 3 yr we now have bred PKO mice 
and have kept some ("-'100) for >12 mo, we have not ob- 
served spontaneous tumors of  any kind. This does not nec- 
essarily call into question the in vivo relevance of perforin 
for tumor control because (a) a mouse facility is a relatively 
protected environment in which mice are not exposed to 
irradiation, toxins, chemicals, or exogenous oncogenic vi- 
ruses; and (b) spontaneous tumor development may be too 
rare for meaningful observation in the few mice that were 
not used for experiments when young and reached an age 
of  >1 yr in our facilities. 
Taken together, our data illustrate that several mecha- 
nisms may control tumor growth; perforin-mediated cyto- 
toxicity by CD8 ÷ CTLs (for MHC class I ÷ tumors) and 
NK cells (for tumors expressing low levels of  MHC class I) 
are of  major importance; Fas/FasL interactions can contrib- 
ute to tumor control in vivo, albeit to a lesser extent than 
perforin-dependent lysis, at least in tumor models using 
several established tumor cell lines or primarily induced 
types of  tumors studied here. 
We thank Gernt Schljff (Department of Immunohematology and Bloodbank, Leiden, The Netherlands) for 
excellent technical assistance, Dr. Stephan Ehl for providing the recombinant vaccinia virus expressing FasU 
and Dr. Paul Klenerman for reviewing the manuscript. 
This study has been financially supported by a Swiss National Science Foundation grant to H. Hengartner 
and P,.M. Zinkernagel, by the canton Ziirich, and by the Human Frontier Science Program. 
Address correspondence to Manes F. van den Broek, Institute of Experimental Immunology, Schmelz- 
bergstr. 12, CH-8091 Zfirich, Switzerland. 
Received for publication 12July 1996 and in revised form 1 August 1996. 
References  
1. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: 
mechanisms operative in the recognition and ehminatxou of 
tumor cells. Adv. Immunol. 49:281-355. 
2. Melief, C.J. 1992. Tumour era&cation by adoptive transfer of 
cytotoxic T lymphocytes. Adv. Cancer Res. 58:143-175. 
3. van Pel, A., P. van der Bruggen, P.C. Couhe, V.G. Brichard, 
B. LethS, B. van den Eynde, C. Uyttenhove, J.C. P, enauld, 
and T. Boon. 1995. Genes coding for tumour antigens recog- 
nized by cytolytic T lymphocytes. Immunol. Rev. 145:229-250. 
4. Chen, L., S. Ashe, W.A. Brady, I. Hellstr6m, K.E. Hellstr6m, 
J.A. Ledbetter, P. McGowan, and P.S. Lindsley. 1992. Co- 
stimulation of antxtumor immumty by the counterreceptor 
for the T lymphocyte molecules CD28 and CTLA-4. Cell. 
71:1093-1102. 
5. L1, Y., P. McGowan, I. Hellstr6m, K.E. Hellstrom, and L. 
Chen. 1994. Costimulatlon of tumor-reactive CD4 + and 
CD8 ÷ T lymphocytes by 137, a natural ligand for CD28, can 
be used to treat established mouse melanoma.J. Immunol. 153: 
421-428. 
6. Hellstr6m, K.E., I. Hellstr6m, and L. Chen. 1995. Can co- 
1788 Tumor Surveillance in Perform-deficient Mice 
 o
n
 April 28, 2005 
w
w
w
.jem.org
D
ow
nloaded from
 
stimulated tumour immunity be therapeutically efficacious? 
hnmunol. Rev. 145:123-145. 
7. Linsley, P.S., andJ.A. Ledbetter. 1995. The role of CD28 re- 
ceptor durxng T cell responses to anngen. Annu. Rev. Immu- 
noL 11:191-219. 
8. Schrler, P.I., lL. Bernards, T.M.J. Vaessen, A. Houweling, 
and A.J. van der Eb. 1983. Expression of class I major hlsto- 
compatibihty antigens switched offby highly oncogemc ade- 
novirus 12 in transformed rat cells. Nature (Lond.). 305:771-775. 
9. Zajlstra, M., and C.J.M. Melief. 1983. Tumorigemcity of cells 
transformed by adenovirus type 12 by evasion of T-cell lm- 
mumty. Nature (Lond.). 305:776--779. 
10. Smith, M.E.F., S.G.E. Marsh, J.G. Bodmer, K. Gelsthorpe, 
and W.F. Bodmer. 1989. Loss of HLA-A,B,C allele products 
and lymphocyte function-associated antigen 3 in colorectal 
neoplasla. Proc. Natl. Acad. Sci. USA. 86:5557-5561. 
11. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of 
mouse mastocytoma P815 after nearly complete rejectmn as 
due to anngen-loss variants rather than to lmmunosuppres- 
sion.J. Exp. Med. 157:1040-1052. 
12. K~irre, K., H.G. Ljunggren, G. Piontek, and R. Kiesshng. 
1986. Selective rejection of H-2-deficaent lymphoma variants 
suggests alternative immunedefence strategy. Nature (Lond.). 
319:675-678. 
13. van den Broek, M.F., D. K~igi, lL.M. Zinkeruagel, and H. 
Hengartner. 1995. Perforln dependence of natural killer cell- 
mediated tumor control m vavo. Eur. J. hnmunol. 25:3514- 
3516. 
14. Kfiga, D., B. Ledermann, K. Bfirki, P. Sefler, B. Odermatt, 
K.J. Olsen, E.R. Podack, P,.M. Zinkernagel, and H. Hen- 
gartner. 1994. Cytotoxlcity mediated by T cells and natural 
killer cells is greatly impaired in perforin-deficmnt trace. Na- 
ture (Lond.). 369:31-37. 
15. Garner, R., C.D. Helgason, E.A. Atkinson, M.J. Pinkoskl, 
H.L. Ostergaard, O. Sorensen, A. Fu, P.H. Lapchak, A. 
Rabinovitch, J.E. McElhaney et al. 1994. Characterizatmn of 
a granule-independent lytic mechanism used by CTL hybr1- 
domas.J. Immunol. 153:5413-5421. 
16. Berke, G. 1993. The functions and mechanisms of actmn of 
cytolytic lymphocytes, In Fundamental Immunology. W.E. 
Paul, editor. Raven Press Ltd., New York. 965-1014. 
17. K~igl, D., B. Ledermann, K. Bfirki, lL.M. Zinkeruagel, and 
H. Hengartner. 1995. Lymphocyte-mediated cytotoxicaty m 
vatro and in VlVO: mechanisms and sagmficance. Immunol. 
Rev. 146:95-116. 
18. Walsh, C.M., M. Matloubaan, C.-C. Liu, R. Ueda, C.G. 
Kurahara, J.L. Chnstensen, M.T.F. Huang, J.D.E. Young, lL. 
Ahmed, and W.lL. Clark. 1994. Immune funcnon in mice 
lacking the perforin gene. Proc. Natl. Acad. Sci. USA. 91: 
10854-10858. 
19. Kojama, H., N. Shinohara, S. Hanaoka, Y. Someya-Shirota, 
Y. Takagaki, H. Ohno, T. Smto, T. Katayama, H. Yaglta, K. 
Okumura et al. 1994. Two distinct pathways ofspecafic kill- 
ing revealed by perforln mutant cytotoxlc T lymphocytes. 
Immunity. 1:357-364. 
20. Kfigi, D., F. Vagnaux, B. Ledermann, K. Bfirki, V. Deprae- 
tere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas 
and perforin pathways as major mechanisms of T cell med> 
ated cytotoxiclty. Science (Wash. DC). 265:528-530. 
21. Lowm, B., M. Hahne, C. Mattmann, andJ. Tschopp. 1994. 
Cytolync T cell cytotoxicity is medmted through perforin 
and Fas lyric pathways. Nature (Lond.). 370:650-652. 
22. Rguv~er ., E., M. Lucaani, and P. Golstem. 1993. Fas involve- 
ment m Ca2+-lndependent T cell mediated cytotoxicity. J. 
Exp. Med. 177:195-200. 
23. K~igi, D., B. Ledermann, K. Btirki, H. Hengartner, and lL.M. 
Zmkernagel. 1994. CD8 + T cell-mediated protection against 
an intracellular bacterium by perforin. Eur. J. Immunol. 24: 
3068-3072. 
24. K~igi, D., B. Odermatt, P.S. Ohashl, lL.M. Zinkernagel, and 
H. Hengartner. 1996. Development of insulitis without &a- 
betes xn transgenic mace lacking perforin-dependent cytotox- 
icity.J. Exp. Med. 183:2143-2152. 
25. K~iga, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Bfirki, 
R.M. Zinkernagel, and H. Hengartner. 1995. The roles of 
pefforin- and Fas-dependent cytotoxaclty in protection against 
cytpathic and noncytopathic viruses. Eur. J. Immunol. 25: 
3256-3262. 
26. Schulz, M., H.J. Schuurman, J. Joergensen, C. Stelner, T. 
Merloo, D. K~igl, H. Hengartner, lL.M. Zinkernagel, M. 
Schreler, K. Bfirki, and B. Ledermann. 1995. Acute rejecnon 
of vascular heart allografts by perforin deficient mice. Eur. J. 
Immunol. 25:474-480. 
27. Walsh, C.M., F. Hayashi, D. Saffran, S. Ju, G. Berke, and 
W.R. Clark. 1996. Cell-mediated cytotoxicity results from, 
but may not be critical for, primary allograft rejectmn.J, hn- 
munol. 156:1436-1441. 
28. Braun, M.Y., B. Lowm, L. French, H. Acha-Orbea, and J. 
Tschopp. 1996. Cytotoxlc T cells deficmnt m both functional 
Fas ligand and perform show residual cytolync activity yet 
lose their capacity to induce lethal graft-versus-host disease. J. 
Exp. Med. 183:657-661. 
29. Fung-Leung, W.P., M.W. Schilham, A. Rahemtulla, T.M. 
K/.indig, M. Vollenwelder, J. potter, W. van Ewijk, and 
T.W. Mak. 1992. CD8 is needed for development of cyto- 
toxic T cells but not for helper T ceils. Cell. 65:443-451. 
30. Shinkal, Y., G. R.athbun, K.P. Lam, E.M. Oltz, V. Stewart, 
M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, 
and F.W. Mt. 1992. RAG-2 deficient mice lack mature lym- 
phocytes owing to inabihty to xmtiate V(D)J rearrangement. 
Cell. 68:855-864. 
31. Doherty, P.O., W.E. Biddison, J.R. Bennink, and B.B. 
Knowles. 1978. Cytotoxac T cell responses in mice anfected 
with influenza nd vaccinia virus vary in magmtude with H-2 
genotype.J. Exp. Med. 148:534-543. 
32. Puddington, L., M.J. Bevan, and L. Lefrangois. 1986. N pro- 
tein is the predomanant antigen recognized by vesicular sto- 
matins virus-specific ytotoxm T cells.J. Virol. 60:708-716. 
33. Toes, R.E.M., R. Offrlnga, R.J.J. Blom, R.M.P. Brandt, A.J. 
van der Eb, C.J.M. Melief, and W.J.M. Kast. 1995. An adeno- 
virus type 5 early region 1B CTL epitope mediating tumor 
eradicataon by CTL clones is downmodulated by an activated 
ras oncogene.J, hnmunol. 154:3396-3405. 
34. Cobbold, S.P., A. Jayasuriya, A. Nasch, T.D. Prospero, and 
H. Waldmann. 1984. Therapy wath monoclonal antibodies 
by eliminanon of T cell subsets in vivo. Nature (Lond.). 312: 
548-552. 
35. Sheenan, K.C.F., N.H. Ruddle, and R.D. Schreaber. 1989. 
Generation and characterizanon of hamster monoclonal nti- 
bodies that neutralize murine tumor necrosas factors.J. Immu- 
nol. 142:3884-3893. 
36. Mackett, M., T. Yflma, J.K. lLose, and B. Moss. 1985. Vac- 
cima virus recombinants: expression of VSV genes and pro- 
tective immumzatmn of mace and cattle. Science (Wash. DC). 
227:433-435. 
37. Ehl, S., U. Hoffmann-Rohrer, S. Nagata, H. Hengartner, 
1789 van den Broek et al. 
 o
n
 April 28, 2005 
w
w
w
.jem.org
D
ow
nloaded from
 
and lL.M. Zinkernagel. 1996. Different susceptibihty of cyto- 
toxic T cells to CD97 (Fas/Apo-1) ligand-mediated cell 
death after activation in vitro versus in vivo.J. Immunol. 156: 
2357-2360. 
38. Lehmann-Grube, F. 1971. Lymphocy~ie choriomeningltlS vi- 
rus. Virol. Monogr. 10:1-11. 
39. Stukart, MJ. ,  A. Vos, and CJ.M. MelieE 1981. Cytotomc T 
cell response against lymphoblasts mfected with Moloney 
(Abelson) murlne leukemia virus. Methodological spects and 
H-2 requirements. Eur. J. Immunot. 11:251-257. 
40. Plrcher, H.P., D. Moskophidis, U. lLohrer, K. Biirki, H. 
Hengartner, and lL.M. Zinkernagel. 1990. Viral escape by se- 
lection of cytotoxic T cell resistant variants in vivo. Nature 
(Lond.). 346:629-633. 
41. Fischer, W.H., P.E. Beland, and W.K. Lutz. 1993. DNA ad- 
ducts, cell proliferation and papilloma latency tame m mouse 
skin after repeated ermal apphcanon of DMBA and TPA. 
Carcinogenesis. 14:1285-1288. 
42. Kiindlg, T.M., M.F. Bachmann, L. Lefranqoxs, L. Pudding- 
ton, H. Hengartner, and lL. Zinkernagel. 1993. Nonimmu- 
nogenic tumor cells may efficiently restimulate tumor ann- 
gen-specific cytotoxic T cells.J. Immunol. 150:4450-4456. 
43. Owen, S.L., R. Radmsky, E. Kruzel, K. Berry, and S. Yone- 
hara. 1994. Antl-Fas on non-hematopoletm umors: levels of 
Fas/APO-1 and bcl-2 are not predicuve for blologncal re- 
sponsiveness. Cancer Res. 54:1580-1586. 
44. Prehn, R.T., and J.M. Mare. 1957. Immumty to methyl- 
cholanthrene-mduced sarcomas. J. Natl. Cancer Inst. 18: 
769-778. 
45. Bubbers, E.J., and F. Lilly. 1977. Selective incorporation of 
H-2 antigenic determinants into Friend virus particles. Nature 
(Lond.). 266:458-459. 
46. Bubbers, E.J., S. Chen, and F. Lilly. 1978. Nonrandom in- 
clusion of H-2K and H-2D antigens m Friend virus particles 
from mice of various strains.J. Exp. Med. 147:340-351. 
47. Levy, J.P., andJ.C. Leclerc. 1977. The munn sarcoma vxrus- 
induced tumor: exception or general model m tumor immu- 
nology? Adv. Cancer Res. 24:1-66. 
48. Stukart, M.J., A. Vos, J. Boes, R.W. Melvold, D.W. Barley, 
and C.J.M. MelieE 1982. A crucial role of the H-2D locus in 
the regulauon of both the D- and the K-associated cytotoxic 
T lymphocyte responses against Moloney leukemia virus 
demonstrated with two D b mutants. J Immunol. 128:1360- 
1364. 
1790 Tumor Surveillance In Perforin-deficlent Mice 
 o
n
 April 28, 2005 
w
w
w
.jem.org
D
ow
nloaded from
 
